{"id":"https://openalex.org/W2116424449","doi":"https://doi.org/10.1086/425581","title":"Capravirine, a Nonnucleoside Reverse\u2010Transcriptase Inhibitor in Patients Infected with HIV\u20101: A Phase 1 Study","display_name":"Capravirine, a Nonnucleoside Reverse\u2010Transcriptase Inhibitor in Patients Infected with HIV\u20101: A Phase 1 Study","publication_year":2004,"publication_date":"2004-11-19","ids":{"openalex":"https://openalex.org/W2116424449","doi":"https://doi.org/10.1086/425581","mag":"2116424449","pmid":"https://pubmed.ncbi.nlm.nih.gov/15529260"},"language":"en","primary_location":{"id":"doi:10.1086/425581","doi":"https://doi.org/10.1086/425581","is_oa":false,"landing_page_url":"https://doi.org/10.1086/425581","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074992735","display_name":"Benjamin E. Gewurz","orcid":"https://orcid.org/0000-0002-3965-3418","observed_orcids":["https://orcid.org/0000-0002-3965-3418"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin\u00a0E. Gewurz","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109516779","display_name":"Mark Jacobs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799594305","display_name":"Saint Francis Memorial Hospital","ror":"https://ror.org/05h29d328","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799594305","https://openalex.org/I2802827176"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Jacobs","raw_affiliation_strings":["HIVCare, St. Francis Memorial Hospital, San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HIVCare, St. Francis Memorial Hospital, San Francisco, California","institution_ids":["https://openalex.org/I2799594305"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108571135","display_name":"Jo Ann Proper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jo\u00a0Ann Proper","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005350858","display_name":"Thomas A. Dahl","orcid":"https://orcid.org/0000-0003-4642-4346","observed_orcids":["https://orcid.org/0000-0003-4642-4346"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas\u00a0A. Dahl","raw_affiliation_strings":["Lexigen Pharmaceuticals, Lexington, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lexigen Pharmaceuticals, Lexington, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110083853","display_name":"Tamio Fujiwara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Tamio Fujiwara","raw_affiliation_strings":["Shionogi Institute for Medical Science, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Shionogi Institute for Medical Science, Osaka, Japan","institution_ids":["https://openalex.org/I4210118477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109548084","display_name":"Bruce Jeffrey Dezube","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce\u00a0J. Dezube","raw_affiliation_strings":["Beth Israel Deaconess Medical Center , 330 Brookline Ave. , CC-913 , Boston , MA 02215","Beth Israel Deaconess Medical Center , Boston , and","Beth Israel-Deaconess Medical Center, Boston;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center , 330 Brookline Ave. , CC-913 , Boston , MA 02215","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center , Boston , and","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Beth Israel-Deaconess Medical Center, Boston;","institution_ids":["https://openalex.org/I1316535847"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4763,"currency":"USD","value_usd":4763},"apc_paid":null,"fwci":1.2644,"has_fulltext":true,"cited_by_count":15,"citation_normalized_percentile":{"value":0.79724128,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"190","issue":"11","first_page":"1957","last_page":"1961"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.9390000104904175},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.9160000085830688},{"id":"https://openalex.org/keywords/antiretroviral-drug-resistance","display_name":"antiretroviral resistance","score":0.8059999942779541},{"id":"https://openalex.org/keywords/antiviral-activity","display_name":"antiviral activity","score":0.8270000219345093},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5389999747276306},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7860000133514404},{"id":"https://openalex.org/keywords/viral-load-reduction","display_name":"viral load reduction","score":0.6200000047683716},{"id":"https://openalex.org/keywords/antiretroviral-experienced-patients","display_name":"antiretroviral-experienced patients","score":0.8550000190734863},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.8090000152587891}],"concepts":[{"id":"https://openalex.org/C156719811","wikidata":"https://www.wikidata.org/wiki/Q28774","display_name":"Reverse transcriptase","level":4,"score":0.7858285903930664},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.7291357517242432},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.6841972470283508},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.5290806889533997},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38991761207580566},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3297501802444458},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.2985396981239319},{"id":"https://openalex.org/C49105822","wikidata":"https://www.wikidata.org/wiki/Q176996","display_name":"Polymerase chain reaction","level":3,"score":0.26644355058670044},{"id":"https://openalex.org/C2776452011","wikidata":"https://www.wikidata.org/wiki/Q311463","display_name":"Sida","level":4,"score":0.21965333819389343},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.1402798891067505},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0962759256362915}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003967","descriptor_name":"Diarrhea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D013457","descriptor_name":"Sulfur Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1086/425581","doi":"https://doi.org/10.1086/425581","is_oa":false,"landing_page_url":"https://doi.org/10.1086/425581","pdf_url":null,"source":{"id":"https://openalex.org/S54542293","display_name":"The Journal of Infectious Diseases","issn_l":"0022-1899","issn":["0022-1899","1537-6613"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Infectious Diseases","raw_type":"journal-article"},{"id":"pmid:15529260","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15529260","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of infectious diseases","raw_type":"Clinical Trial"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.928.7128","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.928.7128","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://jid.oxfordjournals.org/content/190/11/1957.full.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320337376","display_name":"NIH Clinical Center","ror":"https://ror.org/04vfsmv21"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W161540850","https://openalex.org/W1883308443","https://openalex.org/W1963535341","https://openalex.org/W2021877795","https://openalex.org/W2044755757","https://openalex.org/W2055542167","https://openalex.org/W2084702672","https://openalex.org/W2086783015","https://openalex.org/W2099509337","https://openalex.org/W2133336323","https://openalex.org/W2138896835","https://openalex.org/W2139502307","https://openalex.org/W2146329405","https://openalex.org/W2318289184","https://openalex.org/W2321421545"],"related_works":["https://openalex.org/W7096855244","https://openalex.org/W1967671846","https://openalex.org/W2046619137","https://openalex.org/W4206062272","https://openalex.org/W2057426739","https://openalex.org/W2138335480","https://openalex.org/W299209873","https://openalex.org/W2065018074","https://openalex.org/W2147139858","https://openalex.org/W2049328875"],"abstract_inverted_index":{"Capravirine":[0,95],"is":[1],"a":[2,8],"nonnucleoside":[3],"reverse-transcriptase":[4],"inhibitor":[5],"(NNRTI)":[6],"with":[7,52,71],"unique":[9],"resistance":[10,16,30],"profile.":[11],"Although":[12],"single":[13],"mutations":[14,27],"allow":[15],"to":[17,28,31,45,48],"established":[18],"NNRTIs,":[19],"human":[20],"immunodeficiency":[21],"virus":[22],"(HIV)-1":[23],"must":[24],"undergo":[25],"multiple":[26],"achieve":[29],"capravirine.":[32],"In":[33],"the":[34,90],"present":[35],"phase":[36],"1":[37],"study,":[38],"capravirine":[39],"was":[40],"administered":[41],"orally":[42],"for":[43],"up":[44],"28":[46],"days":[47],"55":[49],"HIV-1-infected":[50],"individuals":[51],"CD4+":[53],"T":[54],"lymphocyte":[55],"counts":[56],"of":[57],"50-500":[58],"cells/microL.":[59],"The":[60,76],"most":[61],"frequent":[62],"adverse":[63],"events":[64],"were":[65],"diarrhea":[66],"(5%)":[67],"and":[68],"nausea":[69],"(4%),":[70],"no":[72],"drug-related":[73],"rashes":[74],"observed.":[75],"day":[77],"15":[78],"median":[79],"(mean)":[80],"HIV-1":[81],"load":[82],"decreased":[83],"by":[84],"1.34":[85],"(1.45)":[86],"log(10)":[87],"copies/mL":[88],"in":[89,101],"patients":[91],"receiving":[92],"25":[93],"mg/kg/day.":[94],"demonstrated":[96],"potent":[97],"antiviral":[98],"activity,":[99],"even":[100],"antiretroviral-experienced":[102],"patients.":[103]},"counts_by_year":[{"year":2022,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}